Given that heterozygous GBA gene mutation carriers (severe, mild and low-risk pathogenic mutations) represent increased susceptibility for PD, gait impairment and cognitive dysfunction (Wang et al., 2014), we tested group differences. This evidence concerns the gene GBA1 and Gait disturbance.